Market Overview - The Hang Seng Index fell by 0.29%, down 75 points, closing at 26,124 points, while the Hang Seng Tech Index decreased by 0.09%. The early trading volume in Hong Kong stocks reached HKD 176.3 billion [1]. Pharmaceutical Sector - The pharmaceutical sector experienced a significant decline, with multiple stocks opening down over 10%. Reports indicate that the Trump administration is considering restrictions on Chinese pharmaceuticals. Notable declines include Hansoh Pharmaceutical down 9%, CSPC Pharmaceutical down 7.5%, and Innovent Biologics down 3.3% [1]. Metals Sector - The non-ferrous metals sector saw gains, driven by a quarter-on-quarter increase in basic metal performance. Companies such as China Hongqiao rose by 3.97%, Jiangxi Copper by 3.2%, and China Aluminum by 3.64% [1]. Semiconductor Industry - The semiconductor industry is expected to continue its "AI-driven + self-controlled" dual development trend in the second half of the year. Semiconductor stocks collectively rose, with Hua Hong Semiconductor and SMIC both increasing by over 5% [1]. Telecommunications - ZTE Corporation saw a rise of 7.62%, as the company accelerates its expansion from connectivity to computing power, with institutions optimistic about its stable performance [1]. Virtual Asset Trading - Yunfeng Financial surged over 18%, following a nearly 28% increase the previous day, after receiving approval to provide virtual asset trading services [2]. Fiber Optics - Longi Fiber Optics experienced a rise of over 14%, driven by increased demand for AI-driven data center interconnectivity, with institutions viewing the company as a core beneficiary [2]. Biotechnology - Rongchang Biopharmaceuticals increased by over 5%, as its drug Taitasip became the first biopharmaceutical to apply for listing in the field of Sjögren's syndrome globally [3]. Clinical Trials - Yaojie Ankang-B saw an increase of over 11%, with its market capitalization surpassing HKD 40 billion after receiving approval to conduct Phase II clinical trials for its drug Tienogitini [4]. Technology Sector - Huiju Technology rose over 10% after entering the Hong Kong Stock Connect list, with expectations of rapid growth in its MPO business over the coming years [5]. Strategic Partnerships - Charoen Pokphand International rose by 3% following a strategic partnership with Muyuan Group, as the company is a producer of the antibiotic goldmine under Charoen's umbrella [5]. Market Trends - Shenzhou Holdings increased by over 8%, driven by hot concepts and performance growth propelling its stock price [5].

Core Viewpoint - Goldman Sachs reports that the Trump administration is discussing restrictions on Chinese pharmaceuticals and drafting an executive order aimed at limiting the entry of innovative Chinese drugs into the U.S. market, which could create "headline risk" for the Chinese biotech/pharmaceutical sector and increase stock price volatility [1] Group 1: Short-term Stock Price Risk Analysis - Companies are categorized into three groups based on their global presence and partnerships: - The first group includes companies with established global operations (e.g., BeiGene, Legend Biotech), which are expected to be less affected due to their solid foundations in markets like the U.S. and low expectations for new transactions [2] - The second group consists of companies with strong global partners (e.g., Kelun Biotech, 3SBio, Hansoh Pharmaceutical, Hengrui Medicine), where the impact is minimal as the executive order primarily targets new licensing transactions, leaving already licensed assets largely unaffected [2] - The third group includes companies with high expectations for external licensing that have not yet materialized, further divided into those planning global clinical trials (e.g., Innovent Biologics, Zai Lab, CSPC) who may enhance clinical value through differentiated data, and those unable or unwilling to conduct global trials (e.g., Galactico, Eucure Biopharma, CStone Pharmaceuticals) who may need to expedite transactions before policy implementation [2] Group 2: Long-term Valuation Considerations - The long-term valuation of companies remains dependent on three core factors: - The quality of data and differentiated clinical value of their pipelines [2] - The execution capability of the companies [2] - The financial condition of the companies [2]

Core Viewpoint - The A-share market shows a strong upward trend, with significant gains in sectors such as computing hardware, semiconductors, and liquid-cooled servers, while sports and precious metals sectors remain sluggish [3][4]. Market Performance - The Shanghai Composite Index rose by 1.12%, the Shenzhen Component Index increased by 2.63%, and the ChiNext Index surged by 4.31% [3]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.48 trillion yuan, an increase of 193.8 billion yuan compared to the previous trading day, with over 3,300 stocks rising [4]. Sector Highlights - Notable sectors with significant gains include: - Components: +6.54% - Co-packaged optics (CPO): +6.13% - AI 50 Index: +4.83% - PCB concept: +4.40% - Fiber optic concept: +4.11% [4]. - Semiconductor stocks, particularly computing chips, experienced a notable surge, with companies like Haiguang Information nearing a 20% limit up [6][13]. Individual Stock Movements - Industrial Fulian reached a new historical high, increasing by 8.78% to 58.38 yuan [9]. - In the pork sector, stocks such as Bangji Technology and Lihua Shares saw significant increases, with Bangji Technology hitting the daily limit up [11][12]. International Market Influence - OpenAI reportedly signed a deal to purchase $300 billion worth of computing power from Oracle over five years, leading to a 36% surge in Oracle's stock, which added approximately $250 billion to its market capitalization in a single day [13].

有消息称，美方或将把矛头对准中国创新药BD。隔夜外媒报道，一项草拟的行政命令威胁要切断从中 国引进创新药的通道，一是针对美国制药公司从中国药企收购药物权益的交易，二是试图阻止制药企业 依赖来自中国患者的临床试验数据。 影响多大？分析认为，该草案或类似于去年的生物安全法案，大概率无法落地，但可能会围绕是否发布 进行一系列的博弈。去年CXO已验证医药脱钩断链不可行，相信中国创新药产业也将承受住压力测 试。目前中国已成为全球创新药不可动摇的源头，中国创新药的崛起不可逆转，这是全球创新资源优化 配置的结果。 创新药波动加剧！9月11日，创新药纯度100%的港股通创新药ETF（520880）低开后一度下挫逾7%， 而后震荡回升，午间收跌3.79%。场内或涌入巨量"抄底"资金，520880持续宽幅溢价，溢价率一度飙至 0．99%，半日成交6．81亿元，已大幅超过上日全天成交额。 | 分时 多日 · | | | F9 盘前盘后 宿加 九轮 图线 工具 @ (2 )> | | | | | | 港股通创新药ETF ① | | | --- | --- | --- | --- | --- | --- | --- | --- | - ...

牛市来了还没上车？上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限 量发放！先到先得！ 创新药"难受的一天"！ 早盘，港股市场创新药集体大跌，其抗肿瘤、辅助生殖、创新药、CXO板块跌幅都一度超过6%。A股创 新药也跟随集体走弱，百济神州、益方生物跌超10%，新诺威、华海药业、微芯生物、荣昌生物、药明康 德等多股跌超6%。 不过，值得注意的是，白宫方面表示，没有"积极考虑"该草案。 旗手仍强CALL 消息面上，市场传来一则不利消息。不过，研究机构却集体强CALL，认为此次杀跌是买入良机。并认为 A股和港股医药板块的走势还远没有结束，上涨主升浪还有望中长期持续。 不过，盘中创新药跌幅大幅收窄，益方生物翻红，百济神州跌幅收窄至5%以内，药明康德跌幅约3%。 突然下跌 虽有利空突袭，但资本圈不少人似乎仍认为，创新药杀跌反而是做多机会。 黑天鹅突袭创新药。 今日早盘，港股相关板块全线杀跌。歌礼制药盘中暴跌超16%，基石药业大跌超8%，中国生物制药、百 济神州、石药集团等股票全线大跌。A股创新药亦跟随走弱，泰格医药、百济神州、新诺威、普蕊斯、艾 迪药业等大跌。 随后，A股、港股创新药板块显示出强大 ...

Group 1 - The core viewpoint of the article highlights the volatility in the Hong Kong innovative drug sector, with significant declines in stocks such as Hansoh Pharmaceutical, BeiGene, and CSPC Pharmaceutical, alongside a notable drop in the Hang Seng Medical ETF [1] - A report from The New York Times indicates that the Trump administration is considering stricter restrictions on innovative drugs from China, particularly experimental drugs, which may have limited substantive impact on domestic innovative drug companies [1] - Data from Huatai Securities shows that since 2025, there have been 540 global innovative drug business development transactions with a total disclosed amount of $163.41 billion, of which Chinese innovative drugs accounted for 83 license-out transactions totaling $84.53 billion, indicating the irreversible rise of Chinese innovative drugs [1] Group 2 - The article notes that foreign companies have faced a patent cliff since 2020, necessitating the acquisition of pipelines to fill a market gap exceeding $240 billion over the next decade, leading to increased lobbying efforts [2] - Long-term trends suggest that the aging population in China will drive steady growth in health consumption demand, forming a core logic for investment in the pharmaceutical sector [2] Group 3 - The Hang Seng Medical ETF (159892) is highlighted as a representative of the global pharmaceutical industry, with a decline of 3.3%, and its top ten weighted stocks include several innovative drug companies [3] - The Hong Kong Stock Connect Medical ETF (520510) focuses on CXO and AI healthcare, with a decrease of 1.88%, featuring leading companies such as WuXi Biologics and MicroPort Medical [3]

【导读】光模块、 PCB 概念股拉升走高，四会富仕走出 20cm 涨停，工业富联盘中涨停 中国基金报记者 晨曦 大家好！来一起关注最新的市场行情和资讯～ 9 月 11 日， A 股三大指数开盘涨跌不一。开盘后市场短线跳水，随后拉升回暖。截至发 稿， A 股主要指数集体飘红，深证成指涨超 1% ，创业板指涨 1.7% 。 | 3819.69 | 12683.34 | 2953.41 | | --- | --- | --- | | 上证指数 +0.20% | 深证成指 +1.00% | 创业板指 +1.69% | 盘面上，上午医药生物板块大幅下跌，传媒、纺织服饰、美容护理、社服等板块不振；农业 股盘初走高，光模块、电路板等概念股集体拉升。 | | | Wind热门概念指数 | | | --- | --- | --- | --- | | 覆铜板 4.49% | 电路板 4.50% | 光模块(CPO) 5.82% | 鸡产业 3.07% | | 射频及天线 3.27% | 生物育种 2.02% | 光芯片 3.81% | 服务器 2.95% | | 猪产业 | 玻璃纤维 | 抗生素 | 生物科技等权 | | --- ...

Core Viewpoint - The Hong Kong innovative drug sector experienced a significant drop, with companies like BeiGene, China Biologic Products, CSPC Pharmaceutical Group, and Innovent Biologics seeing declines of over 10% in early trading. However, the Hong Kong Innovative Drug ETF (159567) rebounded, indicating strong investor interest and a potential bottoming out in the market [1] Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) opened low but saw a recovery, with a market price premium of nearly 1% [1] - The ETF recorded a net subscription of 904 million shares during intraday trading, reflecting strong demand from investors [1] Group 2: Industry Outlook - Analysts suggest that the long-term bullish trend for innovative drugs may not be over, as the commercialization value of innovative drug assets driven by China's engineering talent has yet to be fully realized [1] - The valuation of the Hong Kong innovative drug sector remains low, with a high number of business development (BD) deals that are both numerous and certain, indicating a robust future pipeline in areas like small nucleic acids and oral GLP-1 [1] - The performance of the innovative drug, CXO, and biopharmaceutical sectors has shown signs of recovery, with China's pharmaceutical industry now possessing global competitiveness [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, aiming to reflect the performance characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] - Investors can also access the Hong Kong Innovative Drug ETF feeder funds (Class A: 023929, Class C: 023930) for a streamlined investment approach to capitalize on the upward potential of the innovative drug sector [1]

Group 1 - The core point of the news is that the Hong Kong innovative pharmaceutical sector experienced a significant decline, with major stocks dropping over 10% due to reports of potential restrictions on Chinese drugs by the Trump administration [1][2][5] - Key stocks affected include Basilea Pharmaceutica-B, Hansoh Pharmaceutical, and Kelun-B, all of which opened lower by 15%, 14.98%, and 12.97% respectively [1][2] - The decline in the innovative pharmaceutical sector also impacted related ETFs, with several Hong Kong Stock Connect innovative drug ETFs dropping over 6% in early trading [2] Group 2 - The report from The New York Times indicated that the Trump administration is drafting an executive order to impose strict limitations on Chinese pharmaceuticals, particularly experimental drugs, which contributed to the market's reaction [2] - In the U.S. market, companies like BeiGene and Zai Lab saw their stocks drop over 9% following the news [2] - Other sectors, such as technology stocks, also faced declines, with notable drops in companies like Baidu and Alibaba, while gold stocks showed some activity with gains [3] Group 3 - Looking ahead, the outlook suggests that as the A-share market enters a valuation digestion phase, expectations of U.S. Federal Reserve easing may provide marginal support for Hong Kong stock valuations [4] - The Hong Kong internet sector is highlighted for its potential due to self-developed AI chips and cloud business expansion, which could enhance earnings certainty [4] - Overall, the low valuation of Hong Kong stocks, combined with improved asset quality and increased corporate dividends and buybacks, may attract foreign capital inflows [4]

9月11日早盘，港股创新药集体暴跌，恒生生物科技指数一度跌超7%，中国生物制药、翰森制药、石药 集团、诺诚健华、百济神州、药明生物、药明康德（603259）等领跌；恒生医药ETF（159892）、港股 通医疗ETF（520510）跟随指数调整。 ③全球化趋势未发生根本转变，中国创新药凭借其研发效率和成本优势，依然是全球药企重要的合作伙 伴，2025年有望继续达成多项十亿级别以上的对外授权交易。 相关ETF： 港股通医疗ETF（520510）：聚焦CXO+AI医疗等主线，CXO含量全市场领先。 恒生医药ETF（159892）：聚焦创新药，同指数下规模最大，流动性良好。 从海外消息来看，一项草拟的行政命令威胁要切断从中国引进创新药的通道，一是美国制药公司从中国 药企收购药物权益的交易将面临更严格的审查，需接受美国外国投资委员会（CFIUS）的"强制性审 查"，二是要求FDA进行更严格审查并收取更高监管费用，阻止制药企业依赖来自中国患者的临床试验 数据。 以史为鉴，参考2024年生物安全法案对CXO的影响过程，创新药板块在短期内可能受情绪压制，市场 波动或难以避免；但从中长期看，行业向好的基本面并未改变： ①国内创 ...